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Despite their age, DNA cross-linking agents such as 
cisplatin[1] and bendamustine[2] remain useful agents in the 
clinic to treat a number of different cancer types[3].  Through the 
years, many novel cross-linking agents have been designed, 
synthesized and evaluated[4],[5] in an attempt to (a) improve on 
cross-linking efficiency[6], (b) modify the sequence-selectivity of 
cross-linking[7], (c) change the distribution of inter- versus 
intrastrand cross-links [8-10], and/or (d) target different base pair 
combinations[11-13].  For example, the naturally occurring 
pyrrolobenzodiazepine (PBD) molecules, derived from 
Streptomyces species[14-18], are characterized by an N10-C11 
imine group that enables formation of a covalent bond to the C2-
amino group of a guanine base[19], and these have been 
successfully incorporated into PBD dimer structures such as 
DSB-120[20] and SJG-136[21] (Figure 1A) that can form 
sequence-selective G-G cross-links in the DNA minor groove.  
The cytotoxicity of these molecules is thought to be directly 
related to the formation of interstrand cross-links (in this instance 
at Pu-GATC-Py sites[22, 23]), and members of the PBD dimer 
class are now being used as payloads for antibody-drug 
conjugates (ADCs)[24, 25]. Evidence is accumulating to suggest 
additional mechanisms of action including the formation of 
intrastrand cross-links[9, 10, 26] and mono-adducts, the 
inhibition of transcription factor binding[27, 28] and the 
inhibition of enzymes such as endonucleases [29, 30] and RNA 
polymerase[31].  
A related but similar example is the duocarmycin family of 
DNA-interactive agents (e.g., CC1065), also isolated from 
Streptomyces species[32-34] and used as payloads for ADCs[35].  
Members of this family covalently bond to the N3-position of 
adenine bases in the DNA minor groove[36].  In a similar manner 
to other DNA minor-groove binding molecules such as the 
polyamides[37], the ability of these molecules to initially bind to 
DNA is thought to relate to their curved shape which allows them 
to embed in AT tracts of the minor groove where they initially 
form stabilizing non-covalent interactions (e.g., van der Waals 
interactions) with the minor groove walls[38, 39].  However, 
unlike the PBDs, duocarmycin-type molecules are thought to be 
“activated” through a DNA-binding-induced conformational 
change whereby the vinylogous amidic conjugation is disrupted, 
bringing the cyclopropane unit into alignment with the adjacent 
cyclohexadienone system, thus activating it for nucleophilic 
attack, a process known as shape-dependent catalysis[38-41].  
Thus, members of the duocarmycin family are thought to be 
chemically unreactive until they reach their DNA target and 
undergo this activation process[42].  These molecules (i.e., as 
their component CPI units) have also been joined through a 
chemical linker to create analogues such as Bizelesin[43]  
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(Figure 1B) which is capable of forming sequence-selective A-A 
interstrand cross-links in the DNA minor groove.  Other CPI 
dimers have been produced[44], joined through their N3-
positions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  A.  The PBD Dimers (e.g., DSB-120 and SJG-136) which can 
form DNA minor-groove interstrand G-G cross-links;  B. A CPI Dimer (e.g., 
Bizelesin) which can form minor-groove interstrand A-A cross-links;  C. An 
example of a CPI-PBD hybrid molecule that can cross-link A-G base pairs.  
The mode of interstrand cross-linking and likely base-pair span is shown 
above each family structure (covalently modified bases in red).     
 
The incorporation of both GC-interactive and AT-interactive 
moieties into symmetric G-G and A-A dimers led to the concept 
of joining PBD and CPI units together to create hybrid molecules 
capable of forming cross-links to both G and A bases 
simultaneously (Figure 1C), which are the subject of this study.  
Three types of these molecules have been reported in the 
literature[45],[46],[47], and their structures are shown in Figure 
2. 
The objective of this study was to use, for the first time,  
molecular dynamics simulations to predict the preferred DNA 
recognition sequences for the three published types of G-A cross-
linking agents[45],[46],[47] shown in Figure 2, and then compare 
these predictions with the cross-linking sites proposed by the 
authors.  Hurley and co-workers published the first example of a 
CPI-PBD dimer (UTA-6026, 1, Figure 2) in 2001[45], reporting 
that it cross-links the sequence 5’-C(G)AATTA-3’ (covalently-
modified bases underlined; brackets denote base on opposite 
strand), has a CL50 value (a measure of cross-linking potency) of 
between 1-10µM in calf thymus DNA, and an IC50 as low as 
0.047 nM in some tumour cell lines (i.e., colon SW480).  
Interestingly, in their gel studies, cross-linking was not complete 
even at 100µM, suggesting that the molecule is a relatively 
inefficient cross-linking agent.  In 2003, Denny and co-workers 
reported[46] an extensive study of PBD-CPI hybrids which 
differed from the Hurley dimer in containing simple methylene 
linkers between the CPI and PBD units, and these molecules are 
now being developed as payloads for antibody-drug conjugates 
through Genentech.  Their most potent molecule 27eS (2, Figure 
2) had a CL50 value of ~0.01µM toward pcDNA3 plasmid DNA, 
and an IC50 as low as 0.0078 nM in some tumour cell lines (i.e., 
EMT6).  The molecule also had limited antitumour activity in 
human tumour xenograft mouse models.  The authors provided 
some evidence that G-A cross-linking was occurring, but did not 
suggest a specific sequence to which 2 should bind.  Finally, in 
2006 Lee and co-workers synthesized the seco-amino-CI-PBD 
hybrid ‘Compound 11’ (3, Figure 2) which they reported to 
provide a very low degree of cross-linking toward pBR-322 
DNA at 10 µM, and to have an IC50 of 0.56 µM in P815 cells 
after 72 hours exposure.  Based on the results of a thermally-
induced cleavage assay, they reported that 3 forms cross-links at 
the 5’-AATTTTCC(G)-3’ sequence. 
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Figure 2.  Structures of the three published families of PBD-(CPI/seco-CI) 
hybrid molecules capable of interstrand cross-linking between G and A base 
pairs in the DNA minor groove:  The Hurley (1)[45], Denny (2)[46] and Lee 
(3)[47] hybrid dimers. 
During the past six years we have developed molecular 
dynamics simulation methodologies[11, 13, 48] that allow us to 
accurately predict and interpret how both mono-alkylating and 
DNA cross-linking agents of this type interact in the minor 
groove of DNA.  As the hybrid dimer 3 reported by Lee [47] had 
a significantly lower DNA cross-linking potency and in vitro 
cytotoxicity compared to the Hurley (1) and Denny (2) dimers, 
we decided to use our simulation methodologies to compare the 
interaction of the three molecules at their proposed DNA 
recognition sites.  We report here that, although the DNA-
interactivity of hybrid dimers 1 and 2 correlate well with their 
cross-linking activity and cytotoxicity, the Lee dimer 3 does not 
appear to have the correct 3-dimensional shape to fit into the 
DNA minor groove, and, in addition, its two alkylating moieties 
(i.e., the PBD and seco-amino-CI units) cannot orient into the 
appropriate alignment for covalent bonding with the relevant 
DNA bases on either the opposite or same strands of DNA.  
More significantly, the MD simulations predict that the linker is 
of insufficient length to allow the PBD and seco-amino-CI units 
to reach the G and A DNA bases that the authors claim to be 
covalently modified.   
MD simulations were undertaken over a 10ns duration (extended 
methodology presented in Supplementary Material).  When 
comparing the three molecules, RMSD calculations between the 
energy-minimized structures of each adduct and the lowest 
energy snapshot derived from MD simulations provided a 
reflection of the DNA disorder observed during simulations.  
Interestingly, the RMSD calculation results correctly predicted 
the experimentally-derived binding site for 1, suggesting that 
RMSD values may be useful as indicators of DNA-affinity and 
cross-link span.      
The CPI-PBD hybrid UTA-6026 (1) was designed by Hurley 
and co-workers using a molecular modeling approach (details not 
published) to span six base-pairs, covalently binding to a guanine 
(through the PBD) and an adenine (through the CPI moiety)[45].  
An indole group was included as part of the central linking 
moiety to increase interactivity with functional groups in the 
minor groove through van der Waals interactions. Hurley and co-
workers predicted that, for their chosen sequence, the optimal 
methylene linker length between the C8-position of the PBD and 
the amide functionality (connecting to the indole ring) should be 
n = 3 to allow the PBD and CPI units to lie in the correct 
orientation to alkylate DNA co-operatively[45].  Non-denaturing 
gel electrophoresis was used to investigate the cross-linking 
ability of 1, and a thermal cleavage gel-based assay was 
performed to identify adenine cleavage points.  Together, these 
data indicated cross-link formation at two different 5’-
C(G)AATTA-3’ sites (alkylated bases underlined). 
In the present study, molecular dynamics simulations were 
carried out over a 10ns time-scale to confirm the proposed six 
base-pair span of 1, and the interstrand cross-link at 5’-
GCC(G)AATTAGC-3’ as derived from the published 
experimental data.  The simulation results were in full agreement 
with the experimental data.  When mono-covalently bound 
through the CPI moiety alone to position A8 of this sequence, the 
PBD was located close enough to G18 for nucleophilic attack and 
covalent attachment to occur.  Furthermore, when both the PBD 
and CPI units were covalently bound to G18 and A8, 
respectively, in the same sequence, negligible distortion of the 
DNA was observed (i.e., RMSD = 0.78Å, Table 1), with the 
molecule well accommodated in the minor groove (Figure 3).  
Simulations with 1 covalently bound to sequences one base 
shorter and one or two bases longer (i.e., 5’-CAATA-3’, 5’-
CAAATTA-3’ and 5’-CAAAATTA-3’) gave higher RMSD 
values of 1.96, 1.00 and 3.04, respectively, thus supporting the 
preferred 5’-CAATA-3’ sequence (Table 1).  It is noteworthy 
that the difference in RMSD values between the preferred and 
shorter sequence (i.e., 0.78 vs 1.96) was much greater than 
between the preferred and one base-pair longer sequences (i.e., 
0.78 vs 1.00), suggesting that if the preferred sequence were to be 
extended by one base-pair, the ligand may still be able to form 
adducts. It is also interesting that the differences between all of 
these RMSD values for 1 (i.e., 0.78, 1.96, 1.00 and 3.04Å) are far 
smaller than those observed for 2 (i.e., 0.93, 2.42 and 6.45Å). 2 
contains a methylene chain between alkylating moieties, whereas 
1 contains an indole group, which may stabilize the adduct to a 
greater degree than the flexible methylene linker.  
    Non-covalently bound simulations provided a similar pattern 
to dimers 2 and 3 in that the molecule appeared to be restrained 
over a guanine for the duration of the simulation, but clearly 
showed that six base-pairs were being spanned (Figure 3).  Also, 
because this sequence span is independent of the length of the 
DNA sequences being investigated, the Free Energy of Binding 
calculations are similar in each case, and do not reflect the more 
meaningful observations based on RMSD calculations from 
covalently bound simulations. 
 
Figure 3.  Snapshot of an MD simulation of the Hurley hybrid PBD-CPI 
dimer (1) (blue) with its PBD and CPI units covalently bound to the G18 
(magenta) and A8 (yellow) bases, respectively, of the sequence 5’-
GCC(G)AATTAGC-3’, with excellent accommodation in the minor groove 
and little distortion of the central AT base-pairing (cyan).  
Based on a thermally-induced DNA cleavage assay of 3, Lee and 
co-workers[47] proposed that it has a seven base-pair cross-
linking recognition site of 5’-AATTTTCC(G)-3’, and also 
reported a number of mono-alkylation events at 5’-TAA-3’ sites 
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within linearized pBR322 plasmid DNA.  Based on this, we 
initially conducted an MD simulation of the published adduct 
(i.e. 3 covalently cross-linked to the seven base-pair duplex 
sequence 5’-GAATTTTCC(G)C-3’), with the introduction of a 
‘GC-lock’ (i.e., terminal guanine bases) to ensure that the DNA 
duplex remained intact throughout the simulation.  As CPI/CBI-
type molecules are known to be more reactive toward DNA than 
PBD molecules[46], the simulations involved initial covalent 
attachment of just the seco-amino-CI unit, leaving the PBD 
unreacted.  This allowed us to investigate the span of the entire 
hybrid molecule.  Next, the DNA sequence was gradually 
reduced in length to investigate the shortest possible adduct 
which was determined to be 5’-ATTC(G)-3’ (Table 1).  An 
identical set of simulations was then undertaken with both PBD 
and CI covalently bound to guanine and adenine residues, 
respectively, within the same set of sequences.  Finally, 
simulations were undertaken with 3 bound non-covalently in the 
DNA minor groove to enable calculation of free energy of 
binding of the ligand to DNA (Table 1). 
It was immediately evident from the simulations that 3 was 
unable to span the seven base-pair cross-link proposed by Lee 
and co-workers (i.e., 5’-ATTTTCC(G)-3’).  In particular, 
simulations with the molecule bis-covalently bonded to this 
sequence indicated that severe distortion of the DNA helix would 
occur with disruption of base-pairing and extensive minor groove 
widening (Figure 4A and 4C).  This result was also supported by 
RMSD plots of the adduct over the duration of the simulation 
(Supplementary Material), and RMSD calculations between the 
lowest energy conformation of the molecule derived from MD 
simulations and the lowest energy conformation after energy 
minimization (pre-MD simulation).  RMSD values were 
calculated to be 2.45Å, suggesting a high degree of distortion of 
the ligand:DNA complex. Crucially, simulations with only the  
 
 
Table 1. Free Energy of Binding and RMSD calculations for interaction of the PBD-duocarmycin dimer hybrids 1-3 with the 
DNA sequences shown, as calculated over the duration of the MD simulations.  
seco-amino-CI unit covalently bonded to the adenine indicated 
that the PBD moiety is then situated directly over the T6:A15 
base-pair (Figure 4B and 4C), at least two base-pairs away from 
the reacting guanine proposed by Lee and co-workers[49], thus 
rendering the proposed second alkylation event unlikely.  
A similar pattern was evident in simulations involving the six 
base-pair sequence 5’-ATTTTC(G)-3’, where mono-covalent 
simulations indicated difficulty in cross-link formation, and dual-
covalently bound simulations suggested significant DNA 
distortion (indicated by a RMSD value of 5.72 (Table 1).  
Although mono-covalently bound simulations suggested a 
potential cross-link at the four base-pair sequence 5’-ATTC(G)-
3’, dual-covalently bound simulations (RMSD = 1.82)  suggested 
that the five base-pair sequence 5’-ATTTC(G)-3’ should form 
the most favoured adduct. This was supported by the RMSD 
calculations (Table 1), which indicated less distortion for both 
the four and five base-pair adducts (i.e., RMSD = 1.82 and 1.15, 
respectively), suggesting that both might form.   
    Overall these simulations highlighted the importance of DNA 
breathing in the accommodation of ligands in the minor groove.  
Our observation that 3 is likely to cross-link the five base-pair 
DNA sequence 5’-ATTTC(G)-3’ rather than the extended 
sequence 5’-ATTTTCC(G)-3’ as suggested by the authors was 
further supported by the proximal location of the unbound PBD 
imine close to the reacting guanine in the mono-alkylated adduct 
in the former sequence. Although significant distortion was 
observed in simulations when dual-covalently bound to the 
idealized DNA sequence, models suggested that the molecule is 
likely to span five base-pairs (see Supplementary Material for 
molecular model).  Furthermore, as 5’-ATTTC(G)-3’ is  not 
obvious as a potential binding site from the published gel studies, 
it is likely that the authors were observing mono-alkylation rather 
than cross-linking events in their experiments.  
    Non-covalently bound simulations of 3 were also not reflective 
of the reported experimental results.  Previous studies have 
shown that adenine-binding molecules such as the CPI family 
direct the sequence targeting of unsymmetrical PBD-CPI 
hybrids[46].  However, in this case, the non-covalently bound 
simulations suggested that the PBD moiety directs binding due to 
the formation of a sequence-selective H-bond between the lone 
pair of the N10 of the PBD and the exocyclic amine of a guanine 
residue.  As a result, in the case of every non-covalently bound 
simulation undertaken, and thus every Free Energy of Binding 
calculation, the PBD moiety remained restrained over the 
intended reacting guanine (i.e., G14 on the reverse strand in the 
case of 5’-GAATTTTC(G)C-3’), spanning DNA in an A-ring-5’ 
orientation in the process.  As 3 spans four base-pairs, addition of 
an extra thymine base to the centre of the binding site does not 
alter the sequence with which the molecule is interacting, as the 
PBD is restrained over a G:C base-pair. As a result, calculated 
free energy of binding values are similar for all sequences 
analysed.  
Hybrid 
Dimer 
Molecule Span 
(number of base-pairs) 
DNA Sequence  
(Sequence being analysed is 
highlighted in bold and red) 
Free Energy of Binding 
Calculations  
(generated from  
non-covalently bound  
simulations) (kcal/mol) 
RMSD Calculations 
(generated from 
covalently  
bound simulations) 
(Å) 
Base-pairing 
maintained  
during 
simulation? 
(Yes/No) 
      
1 
 
 
 
2 
 
 
 
3 
 
 
5-6 
 
 
 
4-5 
 
 
 
4-5 
 
 
 
5’-GCCAATAGC-3’ 
5’-GCCAATTAGC-3’ 
5’-GCCAAATTAGC-3’ 
5’-GCCAAAATTAGC-3’ 
5’-GCGTATGC-3’ 
5’-GCGTAATGC-3’ 
5’-GCGTAAATGC-3’ 
5’-GCGTAAAATGC-3’ 
5’-GAATTCG-3’ 
5’-GAATTTCG-3’ 
5’- GAATTTTCG-3’ 
5’-GAATTTTCCG-3’ 
 
-55.45 
-54.15 
-54.40 
-54.32 
-41.11 
-41.97 
-38.93 
-41.60 
-48.78 
-51.41 
-52.84 
-52.63 
 
1.96 
0.78 
1.00 
3.04 
0.93 
2.42 
6.45 
5.23 
1.82 
1.15 
5.72 
8.45 
 
Y 
Y 
Y 
N 
Y 
N 
N 
N 
N 
N 
N 
N 
  
 
 
 
 
Figure 4.  A: The PBD-CI hybrid dimer 3 of Lee and co-workers[47] 
covalently bound to an adenine (yellow) and guanine (magenta) (underlined) 
through the CI and PBD units, respectively, in the sequence 5’-
GCATTTTCC(G)C-3’ proposed by the author, illustrating extensive base-
pair distortion (cyan) and minor groove widening;  B: 3 mono-covalently 
bound to A3 (yellow, underlined) of 5’-GAATTTTCCC-3’ through its seco-
amino-CI moiety.  The molecule spans four to five base-pairs (green rod in 
schematic C), with the PBD moiety ideally placed for covalent attack on 
either of the bases at the T7:A14 positions (orange) if they were mutated to 
guanines.  The G12 (magenta), suggested by Lee and co-workers to be the 
target base for covalent interaction of the PBD component of the molecule 
(blue rod in schematic C) would lead to significant distortion of the DNA 
helix (see A).  
     
Bioinformatics analysis of the linearized DNA plasmid pBR322 
suggests 20 potential binding sites for 3 (from within a total of 
4361 bases) based on the proposed preferred five base-pair 5’-
AWWWC(G)-3’ binding site (where W represents adenine or 
thymine, G represents guanine and C is cytosine) from our 
modeling studies.  The relative prevalence of the sequence 5’-
AWWWC(G)-3’ suggests that a significant band in the cross-
linking gel relating to this sequence should have been observed.  
However, as this was not the case, it is likely that other factors 
may contribute to the lack of interaction of 3 with DNA.  In this 
context, it is noteworthy that, unlike the potent PBD dimers in 
the literature (Figure 1A)[50], 3 possesses a linker between the 
C8-position of the PBD and the amidic carbonyl based on two 
methylene groups.  Symmetrical PBD dimers in which the linker 
is odd-numbered (i.e. n = 3 or 5) are known to be more DNA 
interactive and cytotoxic (e.g., 103 more potent in some cancer 
cell lines) than even-numbered equivalent molecules (i.e. n = 2 or 
4), as the alkylating moieties are more-appropriately oriented for 
the alkylation events[51].  Therefore, we considered whether this 
effect could have contributed to the poor cross-linking ability 
observed for 3 by carrying out simulations on analogues 
containing an alternative trimethylene linker (n=3) (data not 
shown).  This led us to conclude that these rules derived from the 
PBD dimers may also apply to asymmetric hybrid dimer 
molecules, whereby odd-numbered methylene linkers appear to 
be preferential for bis-alkylation events to occur.   
For the PBD-CPI hybrids produced by Tercel and co-
workers[46], their thermal cleavage experiments suggested that a 
number of mono-alkylation events occurred between the CPI 
moiety of 2 and adenine bases, and results from their Comet 
assay analysis suggested greater interstrand cross-linking potency 
for some of their hybrid dimers compared to the PBD dimer 
DSB-120[46].  However, potential DNA cross-linking sites were 
not identified in their study.  Therefore, we used our molecular 
dynamics simulations to try to identify potential cross-linking 
sites.   
Starting with a four base-pair sequence (5’-GTAT-3’), an 
increasing number of adenine-thymine base-pairs were inserted 
between the 5’-T and 5’-A bases (i.e., 5’-GT(A)nT-3’), increasing 
the total span of base-pairs up to a maximum of seven (i.e., 5’-
GTAAAAT-3’). A:T base-pairs were selected as the central 
components in an effort to maximise non-covalent interaction 
with functional groups in the DNA minor groove, and minimize 
potential steric hindrance from the C2-amino groups of guanine 
bases.  In a similar manner to the simulations undertaken on the 
other hybrid dimers, the interaction of 2 with DNA was 
simulated in three ways; non-covalently bound, mono-alkylated 
with the CPI moiety covalently bound to an adenine base, and 
dual-alkylated.  These simulations suggested that the four base-
pair sequence 5’-GTAT-3’ is the most favoured cross-linking site 
(Figure 5).  This was mainly reflected in the bis-covalently 
bound simulations, where little distortion of the DNA structure 
was observed (i.e., RMSD = 0.93Å, Table 1), and base-pairing 
was maintained.  Introduction of additional base pairs beyond the 
established four base-pair optimum resulted in increased DNA 
disorder, which was reflected in higher RMSD values (e.g., 
RMSD values of up to 6.45Å in the longer sequences analyzed, 
Table 1). 
 
 
Figure 5.  The PBD-CPI hybrid dimer 2 (“27eS”) synthesised by Denny and 
co-workers[47] (blue) with the CPI and PBD moieties covalently bound to 
both an adenine (yellow) and guanine (magenta), respectively, in the 
idealized sequence 5’-GCGTAT(A)GC-3’ predicted through molecular 
dynamics simulations, illustrating the excellent accommodation of the 
molecule in the minor groove for this sequence.   
 
These results showed that 5’-GWWT-3’ (where W represents 
A or T) should be the most favoured cross-linking site for 2.  In a 
similar manner to simulations of 3, Free Energy of Binding 
A. 
B. 
C. 
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calculations did not reflect the predicted cross-linking sites.  
During simulations between 2 and each sequence, a sequence-
selective hydrogen bond was formed between the C2-amino 
group of guanine and the lone pair of the N10 of the PBD, 
thereby restraining 2 over a guanine base for the duration of the 
simulation.  Therefore, as the span of the molecule is four to five 
base-pairs, there was little difference between each sequence 
from the simulation perspective (Table 1), and so negligible 
differences in Free Energy of Binding values were observed.    
Finally, it is known that symmetrical PBD dimers in which the 
linker attached to the C8/C8’-positions is odd-numbered in length 
(e.g., n = 3 or n = 5) have a higher DNA binding affinity and are 
more cytotoxic (e.g., 103 more potent in some cancer cell lines) 
than even-numbered equivalent molecules (e.g., n = 2 or 4). This 
is thought to be due to the alkylating moieties being in a more 
optimal orientation and alignment for alkylation events to occur 
in the case of odd-numbered linkers[51].  The hybrid dimers 
synthesized by Tercel and co-workers[46] appear to follow this 
rule.  For example, they synthesized and evaluated a series based 
on CPI and PBD moieties separated by a methylene linker (i.e., 
based on 2, Figure 2), with differentiation achieved through 
variation of linker length (i.e., n = 1-5).  Compounds with odd-
numbered linker lengths (in this case n = 3 and n = 5) 
significantly out-performed those with even-numbered linker 
lengths, providing a cross-linking hierarchy of n = 2 < 1 < 4 < 5 
< 3.  This experimental observation is in accord with our models 
of 3, which suggest that the analogue with a linker of n = 3 
should be more DNA-interactive than the n = 2 analogue.  
It is important to acknowledge that this molecular dynamics 
simulation approach may have a number of limitations.  For 
example, one problem is that the covalent binding energy of 
forming just one covalent bond between any ligand and DNA is 
so large (i.e., ~75 kcal/mol per C-N bond) that there is abundant 
energy available to radically distort the DNA structure, and for 
cross-linking agents which form two covalent bonds even more 
free energy is available (i.e., ~150 kcal/mol).  This covalent 
binding free energy is not encompassed in the molecular 
dynamics simulation paradigm, and so this approach may not be 
able to predict the formation of highly distorted DNA adducts 
(e.g., those produced by cross-linking agents such as cis-
platin)[3].  One practical problem when carrying out a molecular 
dynamics simulation is the need to establish which of the many 
conformations formed during the simulations are potentially 
relevant in real life.  In the case of ligand-DNA interactions, if 
the simulations produce solutions that strongly resemble 
canonical B-form DNA with the ligand fitting perfectly in the 
minor groove and making good Van der Waals interactions in all 
directions, then it might be reasonable to assume that such 
"equilibrium" configurations represent plausible structures in real 
life.  Although we cannot be completely confident that the 
conformation chosen post-minimization (i.e., before undertaking 
simulation) is the most biologically relevant, it is evident from 
our results that measuring the degree of distortion over the 
duration of a simulation can provide an insight into cross-linking 
efficiency.  In the case of the molecules studied here, cross-
linking potency, cytotoxicity and degree of distortion of 
ligand:DNA adducts are experimentally correlated, and it is 
gratifying that our MD simulations appear to follow this trend.  
Interestingly, in the case of the PBD dimers (Figure 1A), their 
significant cytotoxicity in cells is thought to be due to their 
perfect fit within the minor groove and consequent lack of 
distortion upon covalent cross-linking, thus avoiding the attention 
of DNA repair enzymes[17].   
In summary, we report the first molecular dynamics 
simulations of the interaction of PBD-CPI hybrid dimers with 
DNA.  In the case of the Hurley hybrid dimer UTA-6026 (1)[45], 
our simulations correctly predicted the cross-link shown to form 
experimentally in a DNA cleavage assay, and this served to 
validate our modeling protocols for use with the other G-A cross-
linking agents, 2 and 3.  However, our modeling studies 
illustrated that the cross-link proposed by Purnell and co-workers 
for 2 is unlikely to occur, and that the results of their reported gel 
studies most likely relate to mono-alkylation rather than cross-
linking events.  Also, our calculations demonstrate that RMSD 
values between the lowest energy derived from energy 
minimization studies and those obtained through molecular 
dynamics simulations are a valuable tool in predicting cross-link 
formation, and may be useful in the design of more potent next-
generation PBD-(CBI/CPI/CI) dimers targeted to specific DNA 
sequences. 
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